Ingrezza-maker Neurocrine brings tardive dyskinesia awareness to the tube

While 2017 saw the entrance of the first two drugs for tardive dyskinesia, the percentage of TD patients who are actually diagnosed remains in the single digits. Neurocrine is looking to change that with a brand-new TV spot.